. Author manuscript; available in PMC: 2020 Apr 1.

Published in final edited form as: Clin Cancer Res. 2019 Jan 7;25(7):2166–2173. doi: 10.1158/1078-0432.CCR-18-1981

Table 3:

Results from the Cox proportional hazards models on progression free survival and overall survival in the subset of patients with both plasma MSC risk level and PD-L1 tumor expression available.

	N	Progression Free Survival						N	Overall Survival
	N	HR	95% CI	p-value	HR^a	95% CI	p-value	N	HR	95% CI	p-value	HR^a	95% CI	p-value
MSC risk level	78							84
High	16	1	-	0.0006	1	-	0.0026	19	1	-	0.0004	1	-	0.0007
Intermediate/Low	62	0.33	0.18-0.62	0.0006	0.35	0.18-0.70	0.0026	65	0.29	0.15-0.58	0.0004	0.28	0.12-0.58	0.0007
PD-L1 expression	78							84
PNC <50%	48	1	-	0.0009	1	-	0.0006	50	1	-	0.0093	1	-	0.0211
PNC ≥50%	30	0.37	0.20-0.66	0.0009	0.35	0.19-0.63	0.0006	34	0.39	0.19-0.79	0.0093	0.43	0.21-0.88	0.0211
MSC and PD-L1	78							84
0 favorable markers	12	1	-		1	-		12	1	-		1	-
1-2 favorable markers	66	0.24	0.11-0.49	0.0001	0.25	0.12-0.56	0.0006	72	0.27	0.13-0.58	0.0008	0.28	0.12-0.65	0.0034

Adjusted for age, sex, smoking status, presence of liver metastasis and for MSC risk level also line of therapy

HR: Hazard Ratio; CI: Confidence Interval; MSC: microRNA signature classifier; PNC: positive neoplastic cells